Published in Medical Letter on the CDC and FDA, February 12th, 2006
The litigation involves patent infringement lawsuits covering Shire's U.S. patents Nos. 6,322,819, 6,605,300 and 6,913,768. As part of the settlement, Impax has confirmed that its proposed generic products infringe Shire's 6,322,819, 6,605,300 and 6,913,768 patents and that the three patents are valid and enforceable.
Impax will be...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.